SUNNYVALE, Calif., Nov. 28,
2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today that its commitment to delivering better,
faster cancer treatment technology and superior service is
resulting in highly satisfied customers. According to the IMV
ServiceTrak™ Radiation Oncology 2022 report, Accuray achieved the
highest score in the industry in Overall Service Performance and
was recognized for Best Service in Radiation Oncology. The IMV
report includes feedback on radiation therapy technologies used in
treating cancer patients in the U.S. and specifically, survey
respondents with hands-on experience using Accuray radiation
therapy delivery systems.
The Accuray Service team is dedicated to ensuring our customers
are successful with our products. According to ServiceTrak, Accuray
also achieved the highest ratio of customers highly satisfied with
Field Service Engineers Overall and top scores in related
categories: Service Follow-Up, Field Service Engineer Competence
and Timely Phone Response. Customers also gave Accuray the highest
score for Overall Manufacturing Performance.
Specifically, CyberKnife® and TomoTherapy®
platform customers*:
- Value the support they receive from Accuray employees: "Accuray
is always available. There has never been once when we have reached
out and not gotten somebody. [The Engineer] provides us with his
direct line so we have service satisfaction that no one can meet."
"They have great equipment and service is good and installation is
awesome. The whole team is awesome to work with. Even
post-installation."
- Appreciate the entire Accuray experience: "They come up with
new technologies. Easy to use system." "They treat linear tumors
better than any machines I know of." "Accuray by far has been the
easiest machine to learn to work on."
"Our goal is to provide our customers with more than just a
machine. We strive to build partnerships that continue throughout
the life of our products and create confidence in our organization
and our team – through upgrade paths that keep customers on the
forefront of technology, service that never quits, and ongoing
opportunities for education," said Scott
Chapman, senior vice president, global service at Accuray.
"According to IMV, this most recent report marks the third
consecutive year we have seen an increase in the percent of
customers likely to repurchase an Accuray radiation delivery
system, suggesting the company's focus and our team's commitment to
excellence in meeting customers' needs is on track."
Accuray has a history of innovation spanning more than 25 years,
culminating in increasingly powerful and flexible options for our
customers to make precise radiation treatments available to more
patients. Upgrades to the CyberKnife and TomoTherapy platforms, in
the form of the CyberKnife S7™ and Radixact® Systems,
and development of the full spectrum of adaptive solutions
including intra-fractional adaption with Synchrony® and
inter-fractional offline adaptation (with PreciseART®),
demonstrate a relentless focus on providing clinically
relevant, leading-edge technologies designed to change
patients' lives for the better.
*IMV ServiceTrak™ Radiation Oncology 2022
report
About IMV
IMV Medical Information Division, part of Science and Medicine
Group, specializes in researching medical imaging and other
advanced healthcare technology markets. IMV's ServiceTrak™ annual
series of reports benchmark and monitor customer satisfaction with
equipment manufacturers, system performance by product type, and
service providers.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions to deliver radiation treatments
for even the most complex cases—while making commonly treatable
cases even easier—to meet the full spectrum of patient needs. We
are dedicated to continuous innovation in radiation therapy for
oncology, neuro-radiosurgery, and beyond, as we partner with
clinicians and administrators, empowering them to help patients get
back to their lives, faster. Accuray is headquartered in
Sunnyvale, California, with
facilities worldwide. To learn more, visit https://www.accuray.com/
or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
The statements made in this press release that are not statements
of historical fact are forward-looking statements and are subject
to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this
press release relate, but are not limited to, Accuray's ability to
continue to meet the service needs of its customers. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
November 3, 2022, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-receives-imv-award-for-best-in-service-in-radiation-oncology-for-2022-301687488.html
SOURCE Accuray Incorporated